Identification of fifteen novel germline variants in the BRCA1 3′UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site

Human Mutation

Volumn 33, Issue 12, 2012, Pages 1665-1675

  Brewster, Brooke L ^a   Rossiello, Francesca ^b   French, Juliet D ^a   Edwards, Stacey L ^a   Wong, Ming ^c   Wronski, Ania ^a   Whiley, Phillip ^d   Waddell, Nic ^d   Chen, Xiaowei ^e   Bove, Betsy ^e   KconFab, ^f   Hopper, John L ^c   John, Esther M ^g,l   Andrulis, Irene ^h   Daly, Mary ^e   Volorio, Sara ^b   Bernard, Loris ^j   Peissel, Bernard ⁱ   Manoukian, Siranoush ⁱ   Barile, Monica ^j   Pizzamiglio, Sara ⁱ   Verderio, Paolo ⁱ   Spurdle, Amanda B ^d   Radice, Paolo ^b,i   Godwin, Andrew K ^e,k   Southey, Melissa C ^c   Brown, Melissa A ^a   Peterlongo, Paolo ^b,i   more..

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^e FOX CHASE CANCER CENTER   (United States)

^f Kathleen Cuningham Consortium for Research into Familial Breast Cancer   (Australia)

^g CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^h MOUNT SINAI HOSPITAL   (Canada)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^k UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^l STANFORD CANCER INSTITUTE   (United States)

more..

Author keywords

3 UTR; BRCA1; Breast cancer; MicroRNAs

Indexed keywords

BRCA1 PROTEIN; MICRORNA; MICRORNA 130; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ARTICLE; BINDING SITE; BREAST CANCER; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC SCREENING; GENETIC VARIABILITY; GERM LINE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN TARGETING; RNA BINDING;

3' UNTRANSLATED REGIONS; ADULT; BASE PAIRING; BASE SEQUENCE; BINDING SITES; BRCA1 PROTEIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CONSERVED SEQUENCE; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GERM-LINE MUTATION; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; MICRORNAS; NUCLEIC ACID CONFORMATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; RNA INTERFERENCE; RNA, MESSENGER;

EID: 84869087925     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22159     Document Type: Article

References (53)

1. Abelson JF, Kwan KY, O'Roak BJ, Baek DY, Stillman AA, Morgan TM, Mathews CA, Pauls DL, Rasin MR, Gunel M, Davis NR, Ercan-Sencicek AG, et al. 2005. Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science 310:317-320.
2. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, et al. 2003. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117-1130.
3. Armes JE, Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ. 1998. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 83:2335-2345.
4. Bakheet T, Frevel M, Williams BR, Greer W, Khabar KS. 2001. ARED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins. Nucleic Acids Res 29:246-254.
5. Baskerville S, Bartel DP. 2005. Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA 11:241-247.
6. Catucci I, Verderio P, Pizzamiglio S, Manoukian S, Peissel B, Barile M, Tizzoni L, Bernard L, Ravagnani F, Galastri L, Pierotti MA, Radice P, Peterlongo P. 2009. SNPs in ultraconserved elements and familial breast cancer risk. Carcinogenesis 30:544-545.
7. Chatterjee S, Pal JK. 2009. Role of 5′- and 3′-untranslated regions of mRNAs in human diseases. Biol Cell 101:251-262.
8. Chen CY, Shyu AB. 1995. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 20:465-470.
9. Chen S, Parmigiani G. 2007. Meta-Analysis of BRCA1 and BRCA2 Penetrance. J Clin Oncol 25:1329-1333.
10. Chen X, Weaver J, Bove BA, Vanderveer LA, Weil SC, Miron A, Daly MB, Godwin AK. 2008. Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk. Hum Mol Genet 17:1336-1348.
11. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller R-U, Straka E, Su L, Burki EA, Crowell RE, Patel R, et al. 2008. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res 68:8535-8540.
12. Clop A, Marcq F, Takeda H, Pirottin D, Tordoir X, Bibe B, Bouix J, Caiment F, Elsen J-M, Eychenne F, Larzul C, Laville E, et al. 2006. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet 38:813-818.
13. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, Scollen S, Baynes C, Ponder BA, Chanock S, Lissowska J, Brinton L, et al. 2007. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39:352-358.
14. den Dunnen JT, Antonarakis SE. 2000. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 15:7-12.
15. Dite GS, Jenkins MA, Southey MC, Hocking JS, Giles GG, McCredie MR, Venter DJ, Hopper JL. 2003. Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst 95:448-457.
16. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R. 2007. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087-1093.
17. Finnerty JR, Wang WX, Hebert SS, Wilfred BR, Mao G, Nelson PT. 2010. The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J Mol Biol 402:491-509.
18. Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, Lidereau R, Mikaelian I, Mazoyer S. 2011. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med 3:279-290.
19. Green S, Issemann I, Sheer E. 1988. A versatile in vivo and in vitro eukaryotic expression vector for protein engineering. Nucl Acids Res 16:369.
20. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. 1990. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684-1689.
21. Heinonen M, Bono P, Narko K, Chang SH, Lundin J, Joensuu H, Furneaux H, Hla T, Haglund C, Ristimaki A. 2005. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res 65:2157-2161.
22. Heinonen M, Fagerholm R, Aaltonen K, Kilpivaara O, Aittomaki K, Blomqvist C, Heikkila P, Haglund C, Nevanlinna H, Ristimaki A. 2007. Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res 13:6959-6963.
23. Heinonen M, Hemmes A, Salmenkivi K, Abdelmohsen K, Vilen ST, Laakso M, Leidenius M, Salo T, Hautaniemi S, Gorospe M, Heikkila P, Haglund C, Ristimaki A, et al. 2011. Role of RNA binding protein HuR in ductal carcinoma in situ of the breast. J Pathol 224:529-539.
24. John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A, Andrulis IL, Anton-Culver H, Boyd N, Buys SS, Daly MB, et al. 2004. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6:R375-R389.
25. Manoukian S, Peissel B, Pensotti V, Barile M, Cortesi L, Stacchiotti S, Terenziani M, Barbera F, Pasquini G, Frigerio S, Pierotti MA, Radice P, Della-Torre G. 2007. Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. Eur J Cancer 43:601-606.
26. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T, Parenti AR, Daidone MG, Bicciato S, Piccolo S. 2010. A MicroRNA targeting dicer for metastasis control. Cell 141:1195-1207.
27. Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M. 2010. Genetic susceptibility to breast cancer. Mol Oncol 4:174-191.
28. McCredie MRE, Dite GS, Giles GG, Hopper JL. 1998. Breast cancer in Australian women under the age of 40. Cancer Causes Control 9:189-198.
29. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, Ramser J, Honisch E, et al. 2010. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42:410-414.
30. Milne RL, Benitez J, Nevanlinna H, Heikkinen T, Aittomaki K, Blomqvist C, Arias JI, Zamora MP, Burwinkel B, Bartram CR, Meindl A, Schmutzler RK, et al. 2009. Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst 101:1012-1018.
31. Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K, Weinstock DM, Gorospe M, Harris AL, Helleday T, Chowdhury D. 2011. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 41:210-220.
32. Neuhausen SL, Ozcelik H, Southey MC, John EM, Godwin AK, Chung W, Iriondo-Perez J, Miron A, Santella RM, Whittemore A, Andrulis IL, Buys SS, et al. 2009. BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research. Breast Cancer Res Treat 116:379-386.
33. Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M, Wojcik SE, Ferdin J, Kunej T, Xiao L, Manoukian S, Secreto G, et al. 2010. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res 70:2789-2798.
34. Ostareck DH, Ostareck-Lederer A, Wilm M, Thiele BJ, Mann M, Hentze MW. 1997. mRNA silencing in erythroid differentiation: hnRNP K and hnRNP E1 regulate 15-lipoxygenase translation from the 3′ end. Cell 89:597-606.
35. Pelletier C, Speed WC, Paranjape T, Keane K, Blitzblau R, Hollestelle A, Safavi K, van den Ouweland A, Zelterman D, Slack FJ, Kidd KK, Weidhaas JB. 2011. Rare BRCA1 haplotypes including 3′UTR SNPs associated with breast cancer risk. Cell Cycle 10:90-99.
36. Peltier HJ, Latham GJ. 2008. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 14:844-852.
37. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, et al. 2000. Molecular portraits of human breast tumours. Nature 406:747-752.
38. Pietshmann A, Mehipour P, Atri M, Hofmann W, Hosseini-Asl S, Scherneck S, Mundlos S, Peters H. 2005. Mutation analysis of BRCA1 and BRCA2 genes in Iranian high risk breast cancer families. J Cancer Res Clin Oncol 131:552-558.
39. Richardson K, Lai C, Parnell L, Yu-Chi L, Ordovas J. 2011. A genome-wide survey for SNPs altering microRNA seed sites identifies functional candidates in GWAS. BMC Genomics 12.
40. Saunus JM, Edwards SL, French JD, Smart CE, Brown MA. 2007. Regulation of BRCA1 messenger RNA stability in human epithelial cell lines and during cell cycle progression. FEBS Lett 581:3435-3442.
41. Saunus JM, French JD, Edwards SL, Beveridge DJ, Hatchell EC, Wagner SA, Stein SR, Davidson A, Simpson KJ, Francis GD, Leedman PJ, Brown MA. 2008. Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR. Cancer Res 68:9469-9478.
42. Sengupta S, Jang B, Wu M, Paik J, Furneaux H, Hla T. 2003. The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. J Biol Chem 278:25227-25233.
43. Sethupathy P, Megraw M, Hatzigeorgiou AG. 2006. A guide through present computational approaches for the identification of mammalian microRNA targets. Nat Methods 3:881-886.
44. Shingara J, Keiger K, Shelton J, Laosinchai-Wolf W, Powers P, Conrad R, Brown D, Labourier E. 2005. An optimized isolation and labeling platform for accurate microRNA expression profiling. RNA 11:1461-1470.
45. Smith LD, Tesoriero AA, Wong EM, Ramus SJ, O'Malley FP, Mulligan AM, Terry MB, Senie RT, Santella RM, John EM, Andrulis IL, Ozcelik H, et al. 2011. Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry. Breast Cancer Res Treat 13:R14.
46. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, et al. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874.
47. Southey MC, Ramus SJ, Dowty JG, Smith LD, Tesoriero AA, Wong EE, Dite GS, Jenkins MA, Byrnes GB, Winship I, Phillips KA, Giles GG, Hopper JL. 2011. Morphological predictors of BRCA1 germline mutations in young women with breast cancer. Br J Cancer 104:903-909.
48. Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson SA, Masson G, Jakobsdottir M, Thorlacius S, Helgason A, Aben KK, Strobbe LJ, et al. 2007. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 39:865-869.
49. Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, Hankinson SE, Hutchinson A, Wang Z, Yu K, Chatterjee N, Garcia-Closas M, et al. 2009. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 41:579-584.
50. Thomas M, Lieberman J, Lal A. 2010. Desperately seeking microRNA targets. Nat Struct Mol Biol 17:1169-1174.
51. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D. 1994. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265:2088-2090.
52. Worm J, Aggerholm A, Guldberg P. 2001. In-tube DNA methylation profiling by fluorescence melting curve analysis. Clin Chem 47:1183-1189.
53. Wynendaele J, Bohnke A, Leucci E, Nielsen SJ, Lambertz I, Hammer S, Sbrzesny N, Kubitza D, Wolf A, Gradhand E, Balschun K, Braicu I, et al. 2010. An illegitimate microRNA target site within the 3′ UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res 70:9641-9649.